Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

These were compared with 245 sites in 49 patients without bone metastases in the Control group.Need captionVariablePCa without bone mets N = 49PCa with bone mets N = 29P valueAge, years (range)74 (53 to 87)71 (52 to 83)0.072BMI (range)23.4 (17.8 to 27.5)22.8 (17.5 to 29.4)0.420Performance status (%)041 (83.7)13 (44.8)0.001*16 (12.2)14 (48.3)22 (4.1)2 (69)Median PSA, ng/mL (range)10.2 (0.3 to 302)269 (0.17 to 5376) < 0.001*Gleason grade group (%)1 or 28 (16.3)00.001*313 (26.5)1 (3.4)415 (30.6)17 (58.6)513 (26.5)13 (37.9)DM (%)2 (4.1)3 (10.3)0.355Habitual drinking (%)11 (22.4)11 (37.9)0.194Current smoking (%)4 (8.2)5 (17.2)0.280Median BAP, μg/L (range)12.2 (4.3 to 26.9)29.6 (7.2 to 567) < 0.001*Median 25(OH)D, pg/mL (range)20.4 (4.6 to 41.2)17.1 (4.4 to 47.8)0.198Free testosterone, pg/mL (range)5.1 (2.0 to 13.4)3.62 (1.2 to 8.5) < 0.001*Androgen-receptor inhibitorBicalutamide49 (100)10 (34.5) < 0.001*Abiraterone03 (9.1)Apalutamide016 (55.2)CHAARTED volume criteriaNo metastasis47 (95.9)0 < 0.001*Low1 (2.0)9 (31.0)High1 (2.0)20 (69.0)Bone metastatic siteL209 (31.0)-L308 (27.6)-L409 (31.0)-Total hip06 (20.7)-Femoral neck03 (10.3)-Others033 (100)-PCa prostate cancer, BMI body mass index, PSA prostate-specific antigen, BAP bone-type alkaline phosphatase*Significant

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A single-center observational study was conducted from February 2020 to January 2023 at Kobe University Hospital.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions

Observational study · International Journal of Clinical Oncology · 2025

Original publication title

Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions

Takuto Hara; Hanako Nishimoto; Tomoaki Terakawa; Yasuyoshi Okamura; Yukari Bando; Hideto Ueki; Kotaro Suzuki; Yoji Hyodo; Jun Teishima; Koji Chiba; Ryosuke Kuroda; Hideaki Miyake

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The present study demonstrates that BMD changes at non-metastatic sites in patients with bone metastases are similar to those in patients without metastases. Monitoring BMD at non-metastatic sites may provide valuable insights into ADT's effects on bone health in prostate cancer patients.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Prostate cancer patients receiving androgen deprivation therapy (ADT) have increased risks of decreased bone mineral density (BMD). However, there are no established guidelines for assessing BMD in patients with bone metastases. The aim of this study was to assess the effects of ADT on bone health by comparing longitudinal changes in BMD between prostate cancer patients with and without bone metastases.

Source: Objectives

Abstract: What methods does the paper describe?

A single-center observational study was conducted from February 2020 to January 2023 at Kobe University Hospital. BMD at the lumbar vertebrae, total hip, and femoral neck was measured at baseline, 6, and 12 months using dual-energy X-ray absorptiometry. Bones were classified into Metastatic Site (with metastases), Non-metastatic Sites (from patients with bone metastases), and Control (patients without metastases) groups. All patients received luteinizing hormone-releasing hormone antagonists or agonists plus oral ARSI or bicalutamide for 1 year.

Source: Methods

Abstract: Results

Among the 78 patients, 35, 110, and 245 bones were classified into the Metastatic Site group, Non-metastatic Sites group, and Control group, respectively. The Metastatic Site group exhibited significantly higher T-scores compared with the other groups (P < 0.001). Repeated measures analysis revealed a statistically significant reduction in T-scores over time across all groups (P < 0.001). However, no significant interaction was observed between group classification and time (P = 0.817).

Source: Results

Abstract: Conclusion

The present study demonstrates that BMD changes at non-metastatic sites in patients with bone metastases are similar to those in patients without metastases. Monitoring BMD at non-metastatic sites may provide valuable insights into ADT's effects on bone health in prostate cancer patients.

Source: Conclusion
Authors’ abstract

Objectives

Prostate cancer patients receiving androgen deprivation therapy (ADT) have increased risks of decreased bone mineral density (BMD). However, there are no established guidelines for assessing BMD in patients with bone metastases. The aim of this study was to assess the effects of ADT on bone health by comparing longitudinal changes in BMD between prostate cancer patients with and without bone metastases.

Methods

A single-center observational study was conducted from February 2020 to January 2023 at Kobe University Hospital. BMD at the lumbar vertebrae, total hip, and femoral neck was measured at baseline, 6, and 12 months using dual-energy X-ray absorptiometry. Bones were classified into Metastatic Site (with metastases), Non-metastatic Sites (from patients with bone metastases), and Control (patients without metastases) groups. All patients received luteinizing hormone-releasing hormone antagonists or agonists plus oral ARSI or bicalutamide for 1 year.

Results

Among the 78 patients, 35, 110, and 245 bones were classified into the Metastatic Site group, Non-metastatic Sites group, and Control group, respectively. The Metastatic Site group exhibited significantly higher T-scores compared with the other groups (P < 0.001). Repeated measures analysis revealed a statistically significant reduction in T-scores over time across all groups (P < 0.001). However, no significant interaction was observed between group classification and time (P = 0.817).

Conclusion

The present study demonstrates that BMD changes at non-metastatic sites in patients with bone metastases are similar to those in patients without metastases. Monitoring BMD at non-metastatic sites may provide valuable insights into ADT's effects on bone health in prostate cancer patients.

Supplementary Information

The online version contains supplementary material available at 10.1007/s10147-025-02711-7.

Publication and source details

Original title: Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions

Takuto Hara; Hanako Nishimoto; Tomoaki Terakawa; Yasuyoshi Okamura; Yukari Bando; Hideto Ueki; Kotaro Suzuki; Yoji Hyodo; Jun Teishima; Koji Chiba; Ryosuke Kuroda; Hideaki Miyake

International Journal of Clinical Oncology · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Kobe University

Open Access funding provided by Kobe University.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T06:49:02.263853+00:00

DOI: 10.1007/s10147-025-02711-7 · PMC11946959